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Abstract
Background: In idiopathic Parkinson’s disease (PD) the clinical features are heterogeneous and include different
predominant symptoms. The aim of the present study was to determine the relationship between subregional
aromatic l-amino acid decarboxylase (AADC) activity in the striatum and the cardinal motor symptoms of PD using
high-resolution positron emission tomography (PET) with an AADC tracer, 6-[
18F]fluoro-L-m-tyrosine (FMT).
Methods: We assessed 101 patients with PD and 19 healthy volunteers. PD was diagnosed based on the UK Brain
Bank criteria by two experts on movement disorders. Motor symptoms were measured with the Unified Parkinson’s
Disease Rating Scale (UPDRS). FMT uptake in the subregions of the striatum was analyzed using semi-automated
software for region-of-interest demarcation on co-registered magnetic resonance images.
Results: In all PD patients, FMT uptake was decreased in the posterior putamen regardless of predominant motor
symptoms and disease duration. Smaller uptake values were found in the putamen contralateral to the side with
more affected limbs. The severity of bradykinesia, rigidity, and axial symptoms was correlated with the decrease of
FMT uptake in the putamen, particularly in the anterior part. No significant correlation was observed between
tremors and FMT uptake.
Conclusions: Decrease of FMT uptake in the posterior putamen appears to be most sensitive in mild PD and
uptake in the anterior putamen may reflect the severity of main motor symptoms, except for tremor.
Background
Cardinal motor symptoms such as bradykinesia, rigidity,
and tremor in Parkinson’s Disease (PD) become appar-
ent after a depletion of dopamine in the striatum to
approximately 20% of normal levels and a reduction in
aromatic L-amino acid decarboxylase (AADC) activity to
5%-20% of normal levels [1,2]. In PD, dopaminergic
hypofunction in the striatum is not homogenous in
association with the selective loss of ventral intermediate
and lateral cell groups of the substantia nigra pars com-
pacta that project to the posterior part of the striatum
[3], although the reason for this selective vulnerability
remains unknown.
Positron emission tomography (PET) is valuable for
assessing altered dopamine function in PD. The first tra-
cer used to visualize and assess the integrity of dopa-
mine presynaptic systems was 6-[
18F]fluoro-L-dopa
(FDOPA), a fluoro-analog of L-dopa [4]. FDOPA is
taken up into the dopaminergic axon terminals and dec-
arboxylated by AADC before being trapped and stored
in synaptic vesicles. FDOPA uptake is highly correlated
with viable dopaminergic cells in neurotoxin-lesioned
monkeys [5] and in postmortem human PD brains [6].
A shortcoming complicating the use of this agent, how-
ever, is that metabolites of FDOPA (such as 3-O-
methyl-[
18F]fluoro-L-dopa, which is formed by the action
of the ubiquitous enzyme catechol-O-methyl-transferase
(COMT)) enter the brain and diminish image contrast.
An alternative agent is the non-catecholic tracer 6-[
18F]
fluoro -L-m-tyrosine (FMT). FMT is also a good sub-
strate for AADC but is not metabolized by COMT;
thus, FMT uptake has approximately twice the sensitiv-
ity of FDOPA uptake and more fully represents the
extent of AADC activity [7-10].
To elucidate the relationship between the main motor
symptoms of PD and subregional AADC activity in the
striatum, we applied a semi-automated segmentation
method for extracting putaminal subregions from
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tered with 3.0-tesla magnetic resonance (MR) images.
Methods
Subjects and clinical evaluation
Our sample consisted of 101 patients with PD and 19
healthy individuals. PD was diagnosed clinically accord-
ing to the UK PD Society Brain Bank criteria [11]. All of
the patients had bradykinesia and at least one of the
three features of PD: 4-6 Hz resting tremor, rigidity, and
postural instability. All of the patients had asymmetric
onset and showed a positive response to dopaminergic
medication. None exhibited atypical symptoms such as
severe gaze palsy or symptomatic dysautonomia. The
control group included healthy individuals with no his-
tory of neurologic or psychiatric diseases.
Motor symptoms were evaluated using the motor
examination part of the Unified Parkinson’s Disease Rat-
ing Scale (UPDRS). Motor subscores were determined as
follows: tremor (motor UPDRS: 20 + 21), bradykinesia
(motor UPDRS: 23 + 24 + 25 + 26), rigidity (motor
UPDRS: 22), and axial (motor UPDRS: 18 + 19 + 27 +
28 + 29 + 30 + 31). The mini-mental state examination
(MMSE) was used to assess cognitive function.
This study was approved by the Institutional Ethics
Committee of Jichi Medical University and all partici-
pants gave written informed consent.
PET imaging
All patients stopped levodopa at least 16 h before PET.
To increase the availability of the tracer, all subjects took
2.5 mg/kg of carbidopa (a peripheral AADC inhibitor)
orally 1 h before FMT injection. Prior to the emission
scan, a 10 min transmission scan was obtained for
attenuation correction. Subsequently, 0.12 mCi/kg of
FMT in saline was infused into an antecubital vein and a
30-90 min static three-dimensional acquisition was
started simultaneously using a PET-CT (GEMINI GXL,
Philips, Amsterdam, The Netherlands). Each subject also
underwent 3.0-tesla MR imaging (Achieva 3.0 T, Philips)
using an inversion recovery (IR) proton density (PD)-
weighted pulse sequence to enhance the contrast of ana-
tomical structures. The PET and MR imaging data were
co-registered with a fusion processing program (Syntegra,
Philips) to produce fusion images. This program provided
manual and point-based image registration as well as
automated methods of gray-value-based image registra-
tion, including a mutual information algorithm [12]. In
addition, an adaptive level set of segmentation was used
for coregistration of CT and MRI imaging data [13].
Semi-automated region of interest analysis
Regions-of-interest (ROIs) in the putamen and caudate
nucleus were defined in three dimensions (3-D)
bilaterally on the co-registered MR images where the
striatum was best visualized. The putamen and the head
of caudate nucleus were delineated by manual inspec-
tion on the three to five adjacent MR planes that corre-
sponded to those planes on the PET images. The
putamen was then automatically divided into three parts
in the rostrocaudal direction using dedicated software
for ROI demarcation. The 3-D ROIs (volumes of inter-
est, VOIs) were extracted automatically by connecting
two-dimensional drawings on each plane using a linear
interpolation algorithm for VOI outlines. For reference,
cerebellar ROIs were also defined in 3-D and located
bilaterally on the cerebellar cortex.
Striatal-to-cerebellum ratio (SCR) values of radioactiv-
ity counts were calculated in the 80-90-min frame for
each structure, using bilaterally averaged cerebellar ROI
data as the denominator. For subregional analysis of
their association with major motor symptoms in the PD
subjects, SCR values from the caudate nucleus and each
part of the putamen were analyzed on the contralateral
to the more affected side of limb.
Statistical Analysis
For comparison of more than two groups, one-way ana-
lysis of variance (ANOVA) was used. When the one-way
ANOVA was significant at p < 0.05, post-hoc compari-
sons were conducted using Scheffé’s test. We examined
the correlation of FMT uptake in each part of the puta-
men with disease duration, and with the symptoms of
bradykinesia, tremor, rigidity, and postural instability
assessed on UPDRS motor scores. Non-linear exponen-
tial regression analysis was applied to assess the rela-
tionship between FMT uptake and disease duration
(Prism, GraphPad Software, La Jolla, CA). SCR values
and the UPDRS scores were compared by Spearman’s
rank correlation coefficient test. P < 0.05 was considered
to indicate a statistically significant difference.
Results
Characteristics of subjects
Demographic and clinical characteristics of the patients
with PD and those of the control subjects are listed in
Table 1 and Table 2. The mean ages of the PD patients
(41 male and 60 female) and the control subjects (6
male and 13 female) were 64.0 years (SD 9.3) and 56.7
Table 1 Clinical Characteristics of the Subjects
Characteristics PD Normal Control p value
Age, year, mean ± SD 64.0 ± 9.3 56.7 ± 11.1 0.005
Male/Female 41/60 6/13 0.542
MMSE 27 ± 2.6 29 ± 1.3 0.005
MMSE, Mini Mental State Examination.
Data are given as mean ± standard deviation (SD) values.
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and severity of symptoms was represented among the
patients. The mean duration of symptoms was 6.0 years
(SD 4.4) and the mean UPDRS motor score was 30.3
(SD 16.0). The right side was more affected in 55
patients.
Subregional analysis of FMT uptake
Figure 1 shows representative images of FMT uptake in
a normal subject and in early- and late-stage PD
patients. Among the patients, FMT uptake showed the
most marked decrease in the posterior putamen, regard-
less of disease duration, but significant decrease was
seen throughout the striatum compared with the healthy
controls. There were significant differences between side
(ipsi- vs. contralateral to the more affected limbs),
region (anterior vs. posterior putamen), and diagnosis
(healthy subjects vs. PD group) (P < 0.001) (Figure 2a).
Asymmetry between the striatum of the more and less
affected sides is preserved, but shows a decrease with
disease progression (Figure 2b).
Decline in FMT uptake with disease duration
Figure 3 shows scatterplots of FMT uptake against
symptom duration in three regions of the putamen con-
tralateral to the more affected limbs. Because age-related
factors such as age at onset of symptoms and age-
related Alzheimer-type pathology may influence disease
duration, we excluded elderly-onset patients (> 70 years
old; n = 19) in this analysis. Exponential regression
curves that best fitted the data for each of the three
regions analyzed are superimposed on the figure.
Between 10 and 15 years of symptom duration, the
FMT for all three curves leveled off to constant values
that showed a statistically significant difference between
the anterior and posterior putamen (p < 0.001). In the
control group, there was no significant difference in
SCR of FMT uptake between younger (< 59 years old,
n = 10) and older (≥ 60 years old, n = 9) subjects (puta-
men, p = 0.87; caudate, p = 0.81).
Correlation of cardinal symptoms and FMT uptake
To minimize the possibility of including patients with
alternative diagnoses, we analyzed patients who had car-
dinal motor symptoms for at least 3 years (n =4 2 ) .W e
obtained positive correlations between the severities of
major motor symptoms: rigidity vs. axial symptoms (r =
0.68, p < 0.001), rigidity vs. bradykinesia (r = 0.56, p <
0.001), bradykinesia vs. postural instability (r =0 . 5 4 ,p <
0.001), and tremor vs. bradykinesia (r = 0.39, p = 0.014).
However, tremor did not have a significant relation with
rigidity (r =0 . 2 0 ,p = 0.20) or with axial symptoms (r =
Table 2 Clinical Charasteristics of the PD patients
Symptom duration, year 6.0 ± 4.4
More affected side Right 55/Left 46
Hoehn-Yahr stage, on 2.4 ± 0.9
Hoehn-Yahr stage, off 3.3 ± 1.1
UPDRS score
Total motor 30.3 ± 16
Bradykinesia 9.86 ± 6.3
Rigidity 6.15 ± 3.8
Axial 9.54 ± 6.2
Tremor 4.80 ± 4.0
UPDRS, Unified Parkinson’s Disease Rating Scale.
Data are given as mean ± standard deviation (SD) values.
Figure 1 Representative FMT-PET images of a healthy individual and PD patients. FMT uptake declines asymmetrically in the early stages,
mostly in the posterior putamen. Left: Regions-of-interest in the putamen. H &Y, Hohen and Yahr stage. The bar indicates the range of
radioactive counts per voxel.
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Page 3 of 60.12, p = 0.45). Axial symptoms, rigidity, and bradykine-
sia scores showed a correlation with FMT uptake in the
contralateral putamen, with the highest correlation in
the anterior putamen, but not in the contralateral cau-
date (Table 3). No significant correlation was evident
between unilateral tremor scores from the most severely
affected limbs and any of the striatal regions. To assess
the potential influence of age, we analyzed older patients
(> 60 years old; n = 25) separately and found similar
correlations between major symptoms and FMT uptake
(Table 4).
Discussion
Idiopathic PD is defined as a synucleinopathy in which
Lewy bodies, pathological aggregations of the synaptic
protein a-synuclein, are found in the dopaminergic neu-
rons in the substantia nigra [14,15]. A reduction of
dopamine in the striatum is a consistent finding in PD,
although the clinical features are heterogeneous and
include different predominant symptoms (resting tre-
mor, bradykinesia, rigidity, or postural instability and
gait disorder) with different rates of progression, and
with or without dementia [16-19]. PET imaging is a
valuable tool for assessing altered dopaminergic function
in the striatum in PD. While FDOPA is suitable for
assessing the metabolism of levodopa, FMT is superior
for estimating AADC activity because it enables the pro-
duction of higher-quality brain images [7,20-22]. The
high resolution of FMT-PET images enables analysis of
Figure 2 FMT uptake in different subregions of the striatum. Mean FMT uptake in different subregions of the striatum in normal control
and PD patients (a). Comparison by side (b) shows persistant side-side asymmetry of putaminal uptake throughout the disease course. *P < 0.05,
** P < 0.01.
Figure 3 Decline in FMT uptake with disease duration.S c a t t e r
plots of FMT uptake against symptom duration in the putamen
contralateral to the more affected limb in PD patients. Exponential
decline is observed in all subregions of the putamen. Reduction of
uptake is prominent at onset of the disease.
Table 3 Correlations of UPDRS scores and FMT uptake
ratio values in the each part of the putamen
Putamen Anterior Middle Posterior Whole
Symptom duration,
year
-0.52
(<0.001)
-0.56
(<0.001)
-0.51
(<0.001)
-0.58
(<0.001)
Total motor score -0.56
(<0.001)
-0.48
(0.002)
-0.41
(0.008)
-0.51
(0.001)
Bradykinesia -0.54
(<0.001)
-0.53
(<0.001)
-0.44
(0.005)
-0.55
(<0.001)
Rigidity -0.50
(0.001)
-0.43
(0.006)
-0.37
(0.018)
-0.44
(0.005)
Axial -0.60
(<0.001)
-0.51
(0.001)
-0.37
(0.016)
-0.50
(0.001)
Tremor 0.069
(0.658)
0.085
(0.587)
0.015
(0.925)
0.050
(0.747)
Data are given as r (p) values. These values were calculated by Spearman’s
rank correlation coefficient test. UPDRS motor score in off-medication state
was evaluated in 42 subjects.
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the striatum.
In the present study, FMT uptake in PD was reduced
in the putamen, particularly in the posterior part. The
anterior-to-posterior gradient of the uptake decrease in
the putamen persisted to the advanced stage of PD.
These results are consistent with those of previous
reports that used other tracers of presynaptic dopami-
nergic terminals, and are considered to reflect the selec-
tive degeneration of nigrostriatal pathways that project
into the posterior part of the putamen [23-25]. The low-
est value of FMT uptake was observed in the posterior
part of the putamen contralateral to the more affected
limbs, even in the early stage of the disease. Because we
analyzed regions in the posterior one-third of the puta-
men on high-resolution images, it is unlikely that the
decreases in uptake were caused by partial volume
effects, which may arise from placement of a small ROI
on inaccurately co-registered images.
Post-mortem investigations of PD demonstrate that
t h er a t eo fd e c r e a s eo fn i g r a ln e u r o n si sr a p i di nt h e
initial stage of the disease: approximately 40%-50% are
lost in the first decade, possibly with a slower rate of
degeneration later on, to finally approach a normal age-
related linear decline [26]. In the present study, loss of
FMT was well fitted to symptom duration using a single
exponential approximation. The exponential model pro-
vided a better fit than a linear model, indicating that the
rate of decline in FMT uptake in the contralateral puta-
men was faster at the beginning of the disease and slo-
wed down as the disease progressed, in agreement with
the results of previous studies that used radiotracers for
imaging nigrostriatal nerve terminals [23-25]. Because
we performed cross-sectional analysis in the present
study, and because all of the participants were on medi-
cation, the data do not provide accurate information
regarding the natural course of the disease, even if PET
measurements were taken in off-medication state. Even
so, the present data are important for assessing the pro-
gression of dopaminergic hypofunction in the striatum
under optimal medical treatment, and can provide the
basis for the development of even better therapeutic
strategies [27,28].
We applied striatal count ratios to analyze the relation-
ships between subregional putaminal FMT uptake and
clinical symptoms. Striatal count ratios using the cerebel-
lum as the denominator have a strong correlation with
striatal uptake constants (Ki values) [29,30]. The present
FMT-PET study showed a significant correlation between
cardinal motor symptoms (rigidity, bradykinesia, and
axial symptoms) and uptake of the tracer in the putamen,
and no significant correlation was found between tremor
score and FMT uptake. These findings are consistent
with the results of previous PET studies [31-33]. The
clinical correlations were more significant in the anterior
part of the putamen than in the posterior part, possibly
reflecting a floor effect for the uptake of FMT in the pos-
terior part of the putamen, where the decrease was severe
even in the early stage of the disease.
The pathophysiological mechanism of tremor is not
fully understood [34]. Tremor does not respond to
L-dopa as well as do bradykinesia and rigidity. The fact
that stereotactic lesion or deep brain stimulation of the
ventral intermediate nucleus (Vim) of the thalamus suc-
cessfully improves tremor indicates a strong association
between non-dopaminergic thalamic and cerebellar sys-
tems, and tremor generation [35,36].
Conclusions
Our results indicate that FMT-PET is useful for evaluat-
ing PD patients from the early stage of the disease and
for studying the relationship between AADC activity
and various clinical features. Decrease of FMT uptake in
the posterior putamen appears to be most sensitive in
mild PD, and uptake in the anterior putamen may
reflect the severity of main motor symptoms, except for
tremor. These data provide an important baseline for
evaluating the effects of surgical interventions, such as
gene therapy for PD.
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ratio values in the each part of the putamen in elder
patients
Putamen Anterior Middle Posterior Whole
Symptom duration,
year
-0.70
(<0.001)
-0.63
(<0.005)
-0.45
(<0.05)
-0.70
(<0.001)
Total motor score -0.56
(<0.01)
-0.50
(<0.05)
-0.37
(0.07)
-0.49
(<0.05)
Bradykinesia -0.46
(<0.05)
-0.46
(<0.05)
-0.34(0.08) -0.46
(<0.05)
Rigidity -0.46
(<0.05)
-0.39
(0.05)
-0.31
(0.12)
-0.37
(0.06)
Axial -0.69
(<0.001)
-0.59
(<0.01)
-0.45
(<0.05)
-0.58
(<0.01)
Tremor 0.26 (0.21) 0.12 (0.58) 0.06 (0.77) 0.14 (0.51)
Data are given as r (p) values. These values were calculated by Spearman’s
rank correlation coefficient test. UPDRS motor score in off-medication state
was evaluated in 25 subjects.
Asari et al. BMC Neurology 2011, 11:35
http://www.biomedcentral.com/1471-2377/11/35
Page 5 of 6Authors’ contributions
SA participated in designing the study, data collection, conducted the
statistical analyses, interpreted data and drafted the first manuscript.
KF participated in data collection and interpretation of data.
AM participated in data collection and interpretation of data.
TS participated in data collection and interpretation of data.
IN participated in designing the study and interpretation of data.
SM conceived the study, participated in its design, data collection,
interpretation of data and drafting the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 6 October 2010 Accepted: 23 March 2011
Published: 23 March 2011
References
1. Hornykiewicz O: Biochemical aspects of Parkinson’s disease. Neurology
1998, 51:S2-9.
2. Nagatsu T, Ichinose H: Molecular biology of catecholamine-related
enzymes in relation to Parkinson’s disease. Cell Mol Neurobiol 1999,
19:57-66.
3. Halliday G: Substantia nigra and locus coeruleus. In The human nervous
system. 2 edition. Edited by: Paxinos G, Mai JK. Amsterdam; Boston: Elsevier
Academic Press; 2004:pp457-458.
4. Garnett ES, Firnau G, Nahmias C: Dopamine visualized in the basal ganglia
of living man. Nature 1983, 305:137-138.
5. Pate BD, Kawamata T, Yamada T, McGeer EG, Hewitt KA, Snow BJ, Ruth TJ,
Calne DB: Correlation of striatal fluorodopa uptake in the MPTP monkey
with dopaminergic indices. Ann Neurol 1993, 34:331-338.
6. Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H,
Kimura H: Human positron emission tomographic [
18F]fluorodopa studies
correlate with dopamine cell counts and levels. Ann Neurol 1993,
34:324-330.
7. DeJesus OT, Flores LG, Murali D, Converse AK, Bartlett RM, Barnhart TE,
Oakes TR, Nickles RJ: Aromatic l-amino acid decarboxylase turnover in
vivo in rhesus macaque striatum: a microPET study. Brain Res 2005,
1054:55-60.
8. DeJesus OT, Holden JE, Endres C, Murali D, Oakes TR, Shelton S, Uno H,
Houser D, Freund L, Perlman SB, et al: Visualization of dopamine nerve
terminals by positron tomography using [
18F]fluoro-β-fluoromethylene-
m-tyrosine. Brain Res 1992, 597:151-154.
9. Doudet DJ, Chan GL, Jivan S, DeJesus OT, McGeer EG, English C, Ruth TJ,
Holden JE: Evaluation of dopaminergic presynaptic integrity: 6-[
18F]
fluoro-l-dopa versus 6-[
18F]fluoro-l-m-tyrosine. J Cereb Blood Flow Metab
1999, 19:278-287.
10. Eberling JL, Bankiewicz KS, O’Neil JP, Jagust WJ: PET 6-[
18F]fluoro-l-m-
tyrosine Studies of Dopaminergic Function in Human and Nonhuman
Primates. Front Hum Neurosci 2007, 1:9.
11. Hughes AJ, Daniel SE, Lees AJ: Improved accuracy of clinical diagnosis of
Lewy body Parkinson’s disease. Neurology 2001, 57:1497-1499.
12. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P: Multimodality
image registration by maximization of mutual information. IEEE Trans
Med Imaging 1997, 16:187-198.
13. Wells WM, Grimson WL, Kikinis R, Jolesz FA: Adaptive segmentation of MRI
data. IEEE Trans Med Imaging 1996, 15:429-442.
14. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J,
Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I: Neuropathological
assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet
Neurol 2009, 8:1150-1157.
15. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M:
Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
16. Halliday GM, McCann H: The progression of pathology in Parkinson’s
disease. Ann N Y Acad Sci 2010, 1184:188-195.
17. Maetzler W, Liepelt I, Berg D: Progression of Parkinson’s disease in the
clinical phase: potential markers. Lancet Neurol 2009, 8:1158-1171.
18. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ: A
clinico-pathological study of subtypes in Parkinson’s disease. Brain 2009,
132:2947-2957.
19. van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ, Marinus J: The
identification of Parkinson’s disease subtypes using cluster analysis: a
systematic review. Mov Disord 2010, 25:969-978.
20. Brown WD, DeJesus OT, Pyzalski RW, Malischke L, Roberts AD, Shelton SE,
Uno H, Houser WD, Nickles RJ, Holden JE: Localization of trapping of 6-
[
18F]fluoro-l-m-tyrosine, an aromatic l-amino acid decarboxylase tracer
for PET. Synapse 1999, 34:111-123.
21. DeJesus OT, Haaparanta M, Solin O, Nickles RJ: 6-fluoroDOPA metabolism
in rat striatum: time course of extracellular metabolites. Brain Res 2000,
877:31-36.
22. Elsinga PH, Hatano K, Ishiwata K: PET tracers for imaging of the
dopaminergic system. Curr Med Chem 2006, 13:2139-2153.
23. Bruck A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO: A follow-up
study on 6-[
18F]fluoro-l-dopa uptake in early Parkinson’s disease shows
nonlinear progression in the putamen. Mov Disord 2009, 24:1009-1015.
24. Lee CS, Schulzer M, de la Fuente-Fernandez R, Mak E, Kuramoto L, Sossi V,
Ruth TJ, Calne DB, Stoessl AJ: Lack of regional selectivity during the
progression of Parkinson disease: implications for pathogenesis. Arch
Neurol 2004, 61:1920-1925.
25. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee CS,
McKenzie J, McCormick S, Samii A, Troiano A, et al: Longitudinal
progression of sporadic Parkinson’s disease: a multi-tracer positron
emission tomography study. Brain 2009, 132:2970-2979.
26. Fearnley JM, Lees AJ: Ageing and Parkinson’s disease: substantia nigra
regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
27. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA,
VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ: Safety and
tolerability of putaminal AADC gene therapy for Parkinson disease.
Neurology 2009, 73:1662-1669.
28. Muramatsu SI, Fujimoto KI, Kato S, Mizukami H, Asari S, Ikeguchi K,
Kawakami T, Urabe M, Kume A, Sato T, et al: A Phase I study of aromatic l-
amino acid decarboxylase gene therapy for Parkinson’s disease. Mol Ther
2010, 18:1731-1735.
29. Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, Margouleff C,
Eidelberg D: Comparative analysis of striatal FDOPA uptake in
Parkinson’s disease: ratio method versus graphical approach. J Nucl Med
2002, 43:1324-1330.
30. Eberling JL, Pivirotto P, Bringas J, Bankiewicz KS: Comparison of two
methods for the analysis of [
18F]6-fluoro-l-m-tyrosine PET data.
Neuroimage 2004, 23:358-363.
31. Martin WR, Wieler M, Stoessl AJ, Schulzer M: Dihydrotetrabenazine
positron emission tomography imaging in early, untreated Parkinson’s
disease. Ann Neurol 2008, 63:388-394.
32. Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T,
Fukumura T, Masuda K, Kato M: Differences in the reduced
18F-Dopa
uptakes of the caudate and the putamen in Parkinson’s disease:
correlations with the three main symptoms. J Neurol Sci 1996,
136:169-173.
33. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ: Which clinical sign of
Parkinson’s disease best reflects the nigrostriatal lesion? Ann Neurol 1997,
41:58-64.
34. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E,
Obeso JA: Initial clinical manifestations of Parkinson’s disease: features
and pathophysiological mechanisms. Lancet Neurol 2009, 8:1128-1139.
35. Diamond A, Shahed J, Jankovic J: The effects of subthalamic nucleus
deep brain stimulation on parkinsonian tremor. J Neurol Sci 2007,
260:199-203.
36. Terao T, Yokochi F, Taniguchi M, Kawasaki T, Okiyama R, Hamada I,
Nishikawa N, Izawa N, Shin M, Kumada S, Takahashi H: Microelectrode
findings and topographic reorganisation of kinaesthetic cells after
gamma knife thalamotomy. Acta Neurochir (Wien) 2008, 150:823-827,
discussion 827.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/11/35/prepub
doi:10.1186/1471-2377-11-35
Cite this article as: Asari et al.: Subregional 6-[
18F]fluoro-L-m-tyrosine
Uptake in the Striatum in Parkinson’s Disease. BMC Neurology 2011
11:35.
Asari et al. BMC Neurology 2011, 11:35
http://www.biomedcentral.com/1471-2377/11/35
Page 6 of 6